- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05156034
A Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SRK-001 in Healthy Participants
A Randomized, Placebo-Controlled, Double-blind, Multiple Dose, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Intravenous Administration of SRK-001 in Healthy Participants
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Groningen, Netherlands, 9728 NZ
- PRA Health Sciences
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participants who have clinical chemistry laboratory values within the acceptable range for the population, as per the investigator judgment
- Body mass index of 18 to 32 kilogram (kg)/ square meter (m^2)
Healthy male participants
- Nonvasectomized male participants must agree to abstain from sexual intercourse or use a condom as well as 1 additional highly effective method of contraception (less than [<]1 percent [%] failure rate) or effective method of contraception with all sexual partners of childbearing potential during the study and for 90 days following the last dose of study intervention
- Must agree not to donate sperm from start of dosing until 90 days beyond the last dose of study intervention
- No restrictions are required for a vasectomized male
Healthy female participants of childbearing potential who have a fertile male sexual partner must be willing and able to practice effective contraception from screening to 90 days after the last dose of the study intervention. Sexually active participants must use a combination of 2 of the following methods of contraception, including at least 1 so-called 'barrier' method:
- hormonal contraceptives (oral, transdermal patches, vaginal, or injectable)
- intrauterine device with or without hormones
- condom, diaphragm, or cervical cap ('barrier' method)
- sexual abstinence, and
- vasectomized partner
- Has been fully vaccinated for COVID-19 with the last dose of vaccine administered at least 3 weeks prior to study intervention administration
Exclusion Criteria:
- For at least 30 days prior to randomization, participants must have no symptoms and/or signs of confirmed or suspected infection (including COVID-19) and must have completed any appropriate anti-infective treatment
- Have any concomitant systemic disorder, human immunodeficiency virus (HIV) infection, current infection with hepatitis B virus (HBV) (that is, positive for hepatitis B surface antigen and/or polymerase chain reaction positive for HBV DNA, hepatitis C virus (HCV) (that is, positive for HCV ribo nucleic acid[RNA]), symptomatic herpes zoster within 6 months prior to screening, an eye condition currently requiring treatment for trauma, contact allergy, postsurgical, or conjunctivitis that may interfere with eye evaluations, active or latent tuberculosis (TB)
- Are currently enrolled in or have participated in greater than (>) 4 clinical trials in the past 12 months involving a study intervention or off-label use of a drug or device, or any other type of medical research judged not to be scientifically or medically compatible with this study or have received a. any nonbiologic IP within 30 days or 5 half-lives (whichever is longer) of their baseline (Day -1) visit, or b. any biologic IP within 3 months or 5 half-lives (whichever is longer) of their baseline (Day -1) visit
- Have an average weekly alcohol intake that exceeds 21 units per week (males) or 14 units per week (females) or are unwilling to stop alcohol consumption from 48 hours prior to each dosing (1 unit = 12 ounce [oz] or 360 milliliter [mL] of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits)
- Drug abuse in the past 12 months and/or show positive findings on drug screening unless they were prescribed by a physician (for example, benzodiazepines)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SRK-001- Dose 1
Participants will receive intravenous (IV) SRK-001 every 2 weeks (Q2W) for 4 doses.
|
Participants will receive IV doses of SRK-001.
|
Experimental: SRK-001- Dose 2
Participants will receive IV SRK-001 every 4 weeks (Q4W) for 2 doses.
|
Participants will receive IV doses of SRK-001.
|
Experimental: SRK-001- Dose 3
Participants will receive IV SRK-001 Q2W for 4 doses.
|
Participants will receive IV doses of SRK-001.
|
Placebo Comparator: Placebo
Participants will receive IV placebo Q2W for 4 doses or Q4W for 2 doses.
|
Participants will receive IV doses of placebo.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs)
Time Frame: Baseline through final follow-up at approximately Day 155
|
Number of participants with one or more TEAEs and SAEs will be reported in the adverse events module.
|
Baseline through final follow-up at approximately Day 155
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area Under the Concentration Versus Time Curve During a Dosing Interval (AUC0-tau) at Steady State
Time Frame: Day 1 (End of the infusion [EOI]) up to Day 155 post EOI
|
Pharmacokinetics (PK) after single and multiple IV dosing.
|
Day 1 (End of the infusion [EOI]) up to Day 155 post EOI
|
Half-Life (t1/2)
Time Frame: Day 1 (EOI) up to Day 155 post EOI
|
PK after single and multiple IV dosing.
|
Day 1 (EOI) up to Day 155 post EOI
|
Concentrations at End of Infusion (Cmax)
Time Frame: Day 1 (EOI) up to Day 155 post EOI
|
PK after single and multiple IV dosing.
|
Day 1 (EOI) up to Day 155 post EOI
|
Concentrations at End of Dosing Interval (Ctrough)
Time Frame: Day 1 (EOI) up to Day 155 post EOI
|
PK after single and multiple IV dosing.
|
Day 1 (EOI) up to Day 155 post EOI
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- SRKMD-2021
- 2021-003991-15 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Participants
-
PfizerRecruitingHealthy Subjects | Healthy ParticipantsUnited States
-
PfizerRecruitingHealthy ParticipantsUnited States
-
PfizerNot yet recruiting
-
Aeovian Pharmaceuticals, Inc.RecruitingHealthy ParticipantsAustralia
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdRecruitingHealthy ParticipantsChina
-
Bristol-Myers SquibbRecruiting
-
AstraZenecaParexelRecruiting
-
ProMis Neurosciences, IncRecruiting
-
Novo Nordisk A/SRecruiting
-
Bristol-Myers SquibbNot yet recruitingHealthy ParticipantsUnited States
Clinical Trials on SRK-001
-
University of BernFreie Universität Berlin; Swiss Transfusion SRCCompletedDepression | PTSD | Quality of Life | Anxiety | Stigma, SocialSwitzerland
-
Scholar Rock, Inc.Active, not recruitingNeuromuscular Diseases | Neuromuscular Manifestations | Atrophy | Muscular Atrophy | Spinal Muscular Atrophy | Muscular Atrophy, Spinal | Spinal Muscular Atrophy Type 3 | SMA | Spinal Muscular Atrophy Type 2 | Anti-myostatinUnited States, Germany, Belgium, Spain, United Kingdom, Netherlands, France, Italy, Poland
-
Scholar Rock, Inc.CompletedNeuromuscular Diseases | Neuromuscular Manifestations | Atrophy | Muscular Atrophy | Spinal Muscular Atrophy | Muscular Atrophy, Spinal | Spinal Muscular Atrophy Type 3 | SMA | Spinal Muscular Atrophy Type 2United States, Spain, Italy, Netherlands
-
Foundation University IslamabadCompletedComparison of SRK-T With Kane Formula for Prediction of Refractive Outcome After PhacoemulsificationCataract; Surgery; Phacoemulsification; Biometry; Intraocular Lens PowerPakistan
-
Toll Biotech Co. Ltd. (Beijing)Recruiting
-
Patagonia Pharmaceuticals, LLCCompletedCongenital IchthyosisUnited States
-
IntegoGen, LLCWithdrawnHidradenitis SuppurativaUnited States
-
JANSSEN Alzheimer Immunotherapy Research & Development...TerminatedAlzheimer's DiseaseUnited States
-
Heartseed Inc.RecruitingHeart Failure | Ischemic Heart DiseaseJapan
-
Frontera TherapeuticsRecruitingBiallelic RPE65 Mutation-associated Retinal DystrophyChina